FibroBiologics (Nasdaq: FBLG) reported an approximately $4.1 million net loss for Q2 2026, the quarter ended June 30, while R&D expense declined to $1.7 million from $2.0 million a year earlier and G&A expense remained about $2.4 million. The central operating development was the start of patient dosing in the Phase 1/2 CYWC628 diabetic foot ulcer trial, while cash and cash equivalents stood at approximately $3.5 million.
Core financial results
The quarterly loss primarily reflected R&D and G&A spending. R&D expense declined because CRO costs decreased by $0.3 million as clinical validation activities shifted toward manufacturing, while the company also capitalized certain costs as R&D supplies.
G&A expense was essentially unchanged. Lower personnel and facilities expenses were offset by higher professional and Nasdaq listing expenses.
| Metric | Reported amount | Comparison or context |
|---|---|---|
| R&D expense | Approx. $1.7 million | Approx. $2.0 million in Q2 2025; down about 15% |
| G&A expense | Approx. $2.4 million | Approx. $2.4 million in Q2 2025; essentially flat |
| Net loss | Approx. $4.1 million | Primarily driven by R&D and G&A expenses |
| Cash and cash equivalents | Approx. $3.5 million | Balance as of June 30, 2026 |
The decline in reported R&D expense should not be read solely as a reduction in development activity, given the shift toward manufacturing and the capitalization of certain costs.
Clinical pipeline progress
FibroBiologics began dosing patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. It manufactured three CYWC628 drug-product batches under cGMP standards; two were released, while the third remained subject to required safety and quality testing.
CYWC628 is the nearest-term clinical focus, but the company also outlined regulatory objectives for its psoriasis, multiple sclerosis, and degenerative disc disease programs.
| Program | Indication | Current status | Next stated milestone |
|---|---|---|---|
| CYWC628 | Diabetic foot ulcers | Phase 1/2 patient dosing underway | Interim results in 2H 2026; primary safety and efficacy results by year-end 2026 |
| CYPS317 | Psoriasis | Preclinical development | Anticipated IND clearance in Q4 2026 |
| CYMS101 | Multiple sclerosis | Preparing regulatory filing | Planned IND submission in Q4 2026 |
| Fibroblast-derived chondrocyte spheroids | Degenerative disc disease | IND amendment planned | Replace single-cell fibroblasts with spheroids derived from the CYWC628 master cell bank |
Management characterized the start of CYWC628 dosing as the beginning of an important clinical period and expects to disclose initial findings during 2026.
Clinical progress is advancing alongside continued financing needs
The approximately $3.5 million quarter-end cash balance makes access to capital important as FibroBiologics conducts the CYWC628 trial and pursues several regulatory milestones. The cash balance and quarterly net loss should not be used to calculate runway directly because the release did not provide operating cash flow, and accounting losses are not equivalent to cash burn.
The company completed a private placement that provided $3.0 million upfront and could generate up to approximately $6.0 million in additional gross proceeds if the related warrants are exercised in full. It also closed a $3.0 million public offering. The potential warrant proceeds are conditional and should not be treated as cash already available to the company.
Recent insider transactions
The supplied insider dataset contains eight direct purchases for which the transaction date, direction, and value were available. These records are presented objectively and do not, by themselves, establish insiders’ views of the company’s prospects.
| Date | Insider and position | Reported purchase price | Transaction value |
|---|---|---|---|
| March 4, 2026 | Peter O’Heeron, CEO | $0.35–$0.41 per share | $19,531 |
| March 4, 2026 | Hamid Khoja, Officer | $0.38 per share | $11,400 |
| March 2, 2026 | Jason D. Davis, CFO | $0.41 per share | $28,973 |
| February 27, 2026 | Ruben A. Garcia, General Counsel | $0.33 per share | $13,056 |
| December 11, 2025 | Ruben A. Garcia, General Counsel | $0.34 per share | $47,600 |
| May 27, 2025 | Hamid Khoja, Officer | $0.84 per share | $16,800 |
| August 12, 2024 | Peter O’Heeron, CEO | $1.91 per share | $16,269 |
| August 12, 2024 | Hamid Khoja, Officer | $1.90 per share | $19,000 |
The dataset’s separate six-month aggregate reported zero transactions, which conflicts with its dated February and March 2026 entries. Two additional 2024 entries for Peter O’Heeron were omitted because the supplied records did not specify the transaction direction or value.
Risks investors need to watch
- Liquidity and funding: Quarter-end cash was approximately $3.5 million, and the company identifies maintaining sufficient capital resources as a risk. Up to $6.0 million of additional private-placement proceeds depends on warrant exercise.
- Early-stage clinical uncertainty: CYWC628 has only recently entered patient dosing. Preclinical findings and early clinical progress may not translate into positive safety or efficacy results.
- Manufacturing execution: The third CYWC628 batch still must pass required safety and quality testing before release, making manufacturing and quality control relevant to trial execution.
- Regulatory timing: The psoriasis IND clearance target, multiple sclerosis IND submission, and degenerative disc disease IND amendment all depend on regulatory and operational execution.
Summary
FibroBiologics’ Q2 2026 results reflected continued losses associated with advancing a clinical-stage pipeline, with R&D expense declining partly because work shifted toward manufacturing and certain costs were capitalized. The start of CYWC628 patient dosing is the main operational milestone, while the upcoming clinical data, regulatory objectives, manufacturing progress, and ability to maintain adequate funding are the principal items to monitor.
Find out more